Relay Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Relay Therapeutics reported an adjusted loss of 37 cents per share for the quarter ended September 30, compared with a larger loss per share in the same quarter last year. Revenue was zero, and the company reported a quarterly loss of $81.75 million.

Confirmed

Global impact / market context

The smaller per-share loss than analysts expected may ease concern about near-term costs, but zero revenue means the company had no sales to offset spending in this quarter. The reported $81.75 million loss makes ongoing cash use a key investor consideration.

Analyst inference

Analysts’ average earnings estimate had fallen about 1.5% over three months, with no revisions in the last 30 days. All 13 listed recommendations were buy or strong buy, while shares were up 106.1% this year despite a 3.4% quarterly decline.

Confirmed

What to watch

1. Future quarterly reports could show whether revenue begins to appear and whether losses narrow; those changes would clarify how much spending is being funded without sales. Analyst inference
2. Watch for analyst estimate revisions after these results, since changes to expected losses would indicate whether analysts view the quarter as altering the company’s outlook. Analyst inference
3. The article reports a $26 median 12-month analyst price target, compared with a last closing price of $17.44; this is an analyst expectation, not a guaranteed outcome. Confirmed

Evidence

• Original source link unavailable